Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. Return on Equity (ROE)
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | (70.8%) | (79.5%) | (26.3%) | (42.7%) | (13.1%) | (25.0%) | (25.9%) | (41.7%) | (84.1%) | (44.1%) | (59.7%) | (26.4%) | (37.5%) | (36.5%) | (49.6%) | (64.7%) | (69.9%) | (106.3%) | (526.1%) | 232.4% |
Alnylam Pharmaceuticals, Inc. (ALNY) Return on Equity (ROE) comparison analysis
ALNY key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
investors
worldwide
FAQ
1) What is Alnylam Pharmaceuticals, Inc.'s Return on Equity (ROE)?
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (2,269.0%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Alnylam Pharmaceuticals, Inc. have been (195.9%) over the past three years, and (165.8%) over the past five years.
2) Is Alnylam Pharmaceuticals, Inc.'s Return on Equity (ROE) Good?
As of today, Alnylam Pharmaceuticals, Inc.'s Return on Equity (ROE) is (2,269.0%), which is lower than industry median of (52.7%). It indicates that Alnylam Pharmaceuticals, Inc.'s Return on Equity (ROE) is Bad.